Switzerland-based Roivant Sciences (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase II study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU), showing the strongest efficacy data in NIU observed to date.
The drug was licensed to Priovant under a deal between Roivant and US pharma giant Pfizer (NYSE: PFE) in 2022. Analysts at Leerink Partners have previously forecast that brepocitinib has a peak sales potential of around $1 billion.
Roivant, whose shares were up 5.5% at $11.00 pre-market, also announced that its board of directors has authorized a share repurchase program for up to $1.5 billion of the company’s common shares, including the repurchase of all 71.3 million shares held by Sumitomo Pharma at a purchase price of $9.10 per share. The aggregate purchase price for the Sumitomo Pharma transaction is about $648.4 million and will reduce Roivant’s shares outstanding as of February 9, 2024 by around 9%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze